PTC Therapeutics
Stock Forecast, Prediction & Price Target
PTC Therapeutics (PTCT) stock Price Target by analysts
$48.5
Potential downside: -1.24%
PTC Therapeutics price prediction
What is PTC Therapeutics stock analysts` prediction?
PTC Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for PTC Therapeutics in the last 3 months, the avarage price target is $48.5, with a high forecast of $NaN. The average price target represents a -1.24% change from the last price of $49.11.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
PTC Therapeutics stock Price Target by analysts
Full breakdown of analysts given PTC Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joel Beatty Robert W. Baird | 0% 0/1 | 9 months ago | $52 5.88% upside | $45.09 | StreetInsider | Previous targets (0) |
Jeffrey Hung Morgan Stanley | 33.33% 1/3 | 11 months ago | $45 -8.36% downside | $38.48 | TheFly | Previous targets (2) |
Colin Bristow UBS | 50% 1/2 | about 1 year ago | $47 -4.29% downside | $34.99 | StreetInsider | Previous targets (1) |
Jeffrey Hung Morgan Stanley | 33.33% 1/3 | about 1 year ago | $32 -34.84% downside | $33.2 | TheFly | Previous targets (2) |
Kelly Shi Jefferies | 0% 0/1 | over 1 year ago | $46 -6.33% downside | $39.81 | StreetInsider | Previous targets (0) |
Paul Choi Goldman Sachs | 0% 0/1 | over 1 year ago | $32 -34.84% downside | $40.12 | StreetInsider | Previous targets (0) |
Jeffrey Hung Morgan Stanley | 33.33% 1/3 | over 1 year ago | $30 -38.91% downside | $28.57 | StreetInsider | Previous targets (2) |
Unknown Goldman Sachs | N/A | over 2 years ago | $35 -28.73% downside | $38.94 | Benzinga | N/A |
Brian Abrahams RBC Capital | 100% 1/1 | about 3 years ago | $46 -6.33% downside | $38.29 | Pulse 2.0 | Previous targets (0) |
Kristen Kluska Cantor Fitzgerald | 0% 0/1 | over 3 years ago | $63 28.28% upside | $43.64 | Pulse 2.0 | Previous targets (0) |
Colin Bristow UBS | 50% 1/2 | about 4 years ago | $45 -8.36% downside | $43.65 | TheFly | Previous targets (1) |
PTC Therapeutics Financial Estimates
PTC Therapeutics Revenue Estimates
PTC Therapeutics EBITDA Estimates
PTC Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $538.59M N/A | $698.80M 29.74% | $937.82M 34.20% | Avg: $833.33M Low: $683.04M High: $916.56M avg. -11.14% | Avg: $927.64M Low: $737.41M High: $1.08B avg. 11.31% | Avg: $927.96M Low: $737.66M High: $1.08B avg. 0.03% | Avg: $1.15B Low: $919.77M High: $1.35B avg. 24.68% |
Net Income
% change YoY
| $-523.90M N/A | $-559.01M -6.70% | $-626.60M -12.09% | Avg: $-203.40M Low: $-413.85M High: $190.83M avg. 67.53% | Avg: $-81.13M Low: $-431.06M High: $237.23M avg. 60.10% | Avg: $-154.16M Low: $-187.59M High: $-113.06M avg. -90.00% | Avg: $-374.19K Low: $-455.33K High: $-274.43K avg. 99.75% |
EBITDA
% change YoY
| $-378.06M N/A | $-372.57M 1.45% | $-330.34M 11.33% | Avg: $-389.02M Low: $-427.88M High: $-318.86M avg. -17.76% | Avg: $-433.05M Low: $-505.28M High: $-344.24M avg. -11.31% | Avg: $-433.20M Low: $-505.46M High: $-344.36M avg. -0.03% | Avg: $-540.14M Low: $-630.24M High: $-429.38M avg. -24.68% |
EPS
% change YoY
| -$7.43 N/A | -$7.79 -4.84% | -$8.37 -7.44% | Avg: -$2.83 Low: -$5.53 High: $2.55 avg. 66.15% | Avg: -$0.69 Low: -$5.76 High: $3.17 avg. 75.62% | Avg: -$2.06 Low: -$2.51 High: -$1.51 avg. -198.36% | Avg: -$0.01 Low: -$0.01 High: -$0 avg. 99.75% |
Operating Expenses
% change YoY
| $881.20M N/A | $1.09B 24.15% | $1.31B 19.90% | Avg: $442.55M Low: $362.74M High: $486.76M avg. -66.26% | Avg: $492.64M Low: $391.61M High: $574.81M avg. 11.31% | Avg: $492.81M Low: $391.75M High: $575.01M avg. 0.03% | Avg: $614.47M Low: $488.46M High: $716.96M avg. 24.68% |
FAQ
What is PTC Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 34.35% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -413.85M, average is -203.40M and high is 190.83M.
What is PTC Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 6.22% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $683.04M, average is $833.33M and high is $916.56M.
What is PTC Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 10.79% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$5.53, average is -$2.83 and high is $2.55.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering PTC Therapeutics stock. The most successful analyst is Joel Beatty.